NewGenIvf Group Limited (NASDAQ: NIVF) generates news across several distinct business lines, reflecting its evolution from a comprehensive fertility services provider in Asia into a diversified, tech-forward group. Company announcements highlight developments in reproductive health solutions, fertility technology, digital assets, and real estate projects.
In healthcare, NewGenIvf issues updates related to its fertility operations and its strategic pivot toward a technology-driven model. News items have covered acquisitions of advanced cytometry intellectual property and MicroSort sperm-sorting technology, which the company describes as central to building a licensing-based fertility technology platform.
Through its NewGenDigital division, the company frequently reports on digital asset and tokenization initiatives. Recent releases include plans and agreements to build a Solana (SOL) treasury, tokenize a private art collection, and act as worldwide tokenization agent for gold-backed assets associated with SAXA, Inc., earning percentage-based fees or commissions on tokenized asset values and sales.
NewGenIvf also issues news about real estate development via NewGenProperty, particularly a joint venture and joint development structure for a luxury project in the Beach District of Ras Al Khaimah in the UAE. Disclosures describe feasibility analyses, projected returns, and changes in profit allocation as the company exercises options under its joint venture agreement with BNW Real Estate Development LLC.
Investors following NIVF news will also see updates on financing arrangements, reverse stock splits, share repurchase programs, and a proposed reverse merger with SAXA, Inc. The Stock Titan NIVF news page aggregates these press releases and related coverage so readers can track how NewGenIvf’s fertility, digital asset, and real estate strategies develop over time.
NewGenIvf Group (NIVF) priced a public offering expected to raise approximately $1.25 million in gross proceeds.
The reasonable-best-efforts offering consists of 17,857,143 ordinary shares or pre-funded warrants in their place. Shares are priced at $0.07 each; warrants cost $0.06999 each and have a $0.00001 exercise price. Closing is expected on or about September 30, 2026. The company expects to use net proceeds and existing cash to invest in K25.ai, restructure debt securities, and manufacture and deploy Nodexus machines, as well as for working capital and general corporate purposes. The SEC declared the offering registration statement effective on September 28, 2026.
NewGenIVF (Nasdaq: NIVF) announced that it has completed an exchange agreement with a certain institutional investor, under which the investor’s existing convertible notes were exchanged for a new senior convertible note on amended terms. The exchange closed on August 14, 2026.
The restructuring removes a prior mandatory requirement that a significant percentage of proceeds from new capital raises be used to prepay the notes under the June 16, 2026 Repurchase and Forbearance Agreement. The new note also includes a leak-out framework and other modified terms intended to give NewGen greater flexibility in managing future financing. The company said it continues to evaluate additional opportunities to further optimize its capital structure.
NewGen (Nasdaq: NIVF) reported that its agreed 13% stake in K25.ai, based on K25.ai’s recently closed Series A round implying a US$200 million valuation, is now valued at approximately US$26 million, representing an expected unrealized gain of about US$8.5 million, subject to completion of the related share purchase agreements.
According to NewGen, this appreciation further strengthens its 2026 financial position following net profit of US$9.9 million for the year ended December 31, 2025 and net assets of about US$25.98 million at that date. The company also expects its total outstanding Class A ordinary shares to reach roughly 5.9 million after completing the issuance of 2,500,000 new shares announced on July 27, 2026.
NewGenIVF Group (Nasdaq: NIVF) entered a definitive agreement to acquire an additional 3% equity interest in K25.ai at a US$250 million equity valuation, representing a US$7.5 million follow‑on investment after K25.ai’s community beta and early user traction.
Upon completion, NewGen’s ownership in K25.ai is expected to rise from 10% to 13%. As consideration, NewGen expects to issue about 2.5 million Class A ordinary shares, increasing total shares outstanding to roughly 5.9 million. According to NewGen, this should lift its market capitalization above the US$5 million threshold and support ongoing Nasdaq listing compliance. The new valuation implies NewGen’s existing 10% stake is worth US$25 million, versus an original investment cost of US$10 million, highlighting a significant mark‑up on its prior entry valuation of US$100 million for K25.ai.
NewGenIVF Group (Nasdaq: NIVF) reported that portfolio company K25.ai has closed a Series A round, reaching a post-money valuation of US$200 million, up from US$100 million in its Pre-A round completed less than 60 days earlier.
NewGen invested US$10 million in K25.ai’s Pre-A round for an approximate 10% ownership stake, which is now valued at about US$20 million. According to NewGen, this implies an unrealized gain of roughly US$10 million, expected to be booked in 2026. The company describes this outcome as aligned with its diversified growth strategy across AI, digital assets, real estate, and healthcare.
K25.ai, an AI-native livestream prediction market platform, has closed a Series A investment round with strategic support from Amber Group, reaching a post-money valuation of US$200 million, which the company says doubles its valuation in under 60 days.
The round follows an oversubscribed Pre-A led by Nasdaq-listed NewGenIVF Group (Nasdaq: NIVF), making Amber Group the second institutional backer. According to K25.ai, the funding and partnership will support product development, global expansion, institutional liquidity infrastructure and its creator ecosystem.
NewGen (Nasdaq:NIVF) received an independent Big Four valuation of about US$19 million for its planned UAE-based cell sorting and cytometry leasing entity, as of May 31, 2026.
The business targets the fast-growing UAE/GCC IVF and medical tourism market and will be led regionally by Senior Strategic Advisor Nadeem Malik.
NewGen (Nasdaq: NIVF) increased total outstanding shares to 10,073,535 after issuing 3,666,667 new shares tied to acquiring a 10% equity interest in K25.ai. Market capitalization was US$7,631,710 on June 18, 2026.
According to NewGen, this valuation is below its US$25.98 million net asset value as of December 31, 2025, and follows a US$10 million investment in K25.ai, supporting a strategic pivot toward AI, digital platforms, and a digital assets treasury strategy while aiming to satisfy Nasdaq’s proposed US$5 million MVLS threshold.
NewGen (Nasdaq:NIVF) agreed to invest an additional US$4 million in K25.ai, completing its aggregate US$10 million commitment. This closes K25.ai’s US$10 million Pre-A round at a US$100 million valuation and is expected to raise NewGen’s ownership to 10%.
NewGen also holds exclusive Asia-Pacific agency rights with K25.ai, aligning it with K25.ai’s product launch, regional commercialization and Series A-funded expansion.
NewGen (Nasdaq: NIVF) entered a Repurchase and Forbearance Agreement with a significant investor to repurchase all outstanding senior convertible notes and warrants previously issued to that investor.
The investor will forbear conversions and exercises while NewGen makes scheduled installment payments through late 2027, aiming to simplify its capital structure and remove potential equity dilution.